芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的有效性Meta分析

Meta-Analysis of the Effectiveness of Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure

目的:运用Meta分析芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的有效性。方法:检索CBM、CNKI、Pubmed、Embase。检索时间从建库至2021年8月10日。搜索芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床随机对照试验。3名研究者独立进行筛选、提取数据。依据Cochrane系统评价手册进行文献质量评价。以RevMan5.4软件进行异质性检验及Meta分析。结果:共纳入7项随机对照研究,共涉及673例患者。Meta分析结果显示:芪苈强心胶囊联合沙库巴曲缬沙坦较单用沙库巴曲缬沙坦能显著提高慢性心力衰竭患者的LVEF (MD 4.80, 95% CI [3.49, 6.11], P < 0.000)和6-MWT (MD 85.20, 95% CI [16.50, 153.91], P = 0.02),并降低慢性心力衰竭患者的NT-proBNP (MD −258.76, 95% CI [−383.00, −134.52], P < 0.000)。结论:芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭效果显著,能进一步提高LVEF和6-MWT,降低NT-proBNP。

Objective: To analyze the effectiveness of Qiliqiangxin Capsules combined with Sacubitril/Valsartan in the treatment of chronic heart failure using Meta. Methods: Search CBM, CNKI, Pubmed, Embase. The search time is from the establishment of the database to August 10, 2021. Search for clinical randomized controlled trials of Qiliqiangxin Capsules combined with Sacubitril/Valsartan in the treatment of chronic heart failure. Three researchers independently screened and extracted data. According to the Cochrane systematic review manual, the quality of the literature was evaluated. RevMan5.4 software was used for heterogeneity test and Meta-analysis. Results: A total of 7 randomized controlled studies were included, involving a total of 673 patients. Meta-analysis results show that Qiliqiangxin capsule combined with Sacubitril/Valsartan can significantly increase the LVEF of patients with chronic heart failure (MD 4.80, 95% CI [3.49, 6.11], P < 0.000) and 6-MWT (MD 85.20, 95% CI [16.50, 153.91], P = 0.02), and reduce NT-proBNP (MD −258.76, 95% CI [−383.00, −134.52] in patients with chronic heart failure, P < 0.000). Conclusion: Qiliqiangxin capsule combined with Sacubitril/Valsartan has a significant effect in the treatment of chronic heart failure, which can further increase LVEF and 6-MWT and reduce NT-proBNP.